Jaguar Health announces issuance of U.S. patent for SBS treatment

Napo Pharmaceuticals announced that the United States Patent and Trademark Office on October 10, 2023 issued a new U.S. patent to Napo for methods for treating short bowel syndrome, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug. Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease with intestinal failure in the US, European Union, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID for these debilitating conditions.